Previous 10 | Next 10 |
MDxHealth SA ( NASDAQ: MDXH ) has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences ( NASDAQ: EXAS ) as well as the latter's urology sales and marketing team. Under the deal, MDxHealth ( MDXH ) paid $25M in cash, plus anothe...
Exact Sciences ( NASDAQ: EXAS ), a provider of cancer diagnostic tests, lowered its full year guidance on Tuesday despite reporting better than expected financials for 2Q 2022 on the back of strong screening revenue. Revenue for the quarter surged ~20% to $521.6M as Sc...
Exact Sciences press release ( NASDAQ: EXAS ): Q2 GAAP EPS of -$0.94 beats by $0.14 . Revenue of $521.64M (+20.0% Y/Y) beats by $25.5M . The company anticipates revenue of $1.98B - $2.02B during 2022 vs. prior view of $1.985B - $2.032B and consensus of $2.02B. ...
Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients PR Newswire ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulatin...
Exact Sciences Announces Second Quarter 2022 Results PR Newswire Second quarter highlights Total second quarter revenue of $522 million , including Screening revenue of $354 million , Precision Oncology revenue of $154 million , and COVID-19 testing...
Shares of cancer diagnostics concern Veracyte, Inc. have shot up approximately 60% over the past month, snapping a deep decline. That said, valuations were stratospheric (22.6x FY21 sales at their peak), but shares of unprofitable Veracyte now trade at just under seven times FY22E sal...
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today I want to discuss several Cathie Wood stocks to buy on the dip. They are big holdings in her portfolios and are likely to see big gains once the market shakes out of its current downtrend. Sometimes it’s easi...
Cathie Wood had an amazing run in 2020. Her family of growth-oriented exchange-traded funds ( ETFs) under the Ark Invest banner has fallen on hard times over the last 18 months. Wood isn't giving up. She's still adding to and subtracting from her funds. What is she buying now? Wood ...
Patience is a virtue, or so says an old proverb. That sentiment certainly applies to the stock market. The longer one holds shares of great companies, the greater the potential for compounding to work its magic. That's why the buy and hold strategy works. However, it can be tough to find qu...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...